Bio-tech company
BeiGene, known for its oncology expertise, remains active with major proceedings. Notably, the company recently celebrated victory over Pharmacyclics in a
patent dispute. It was also successful in receiving a Regulatory
Filing for ADS Registration, and managed to successfully pass key resolutions at an EGM. BeiGene made headlines as it
changes its Nasdaq Ticker Symbol to “ONC”. They continued on a winning run as they received positive
CHMP Opinions for their treatments of cancer. Their expansion strategy sees them plan a move to
Switzerland and proposed a domicile change.
In a major leadership shakeup,
Giancarlo Benelli was announced as the Head of Europe while other significant updates to the Commercial Leadership Team were made. A collaboration with BostonGene to advance biomarker discovery in Mantle cell lymphoma also showcases their commitment to finding new treatments for cancer. BeiGene experienced a drawdown when they had to
discontinue a key lung cancer drug due to trial miss. Yet, they showed resilience with the stock soaring 3.2% among other positive financial forecasts. They've announced an eminent
name change from BeiGene to BeOne Medicines, reaffirming their mission.
BeiGene, Ltd. News Analytics from Tue, 23 Jul 2024 07:00:00 GMT to Sat, 03 May 2025 11:09:30 GMT -
Rating 2
- Innovation 6
- Information 9
- Rumor -1
